Enanta Pharmaceuticals (ENTA) late Monday reported a fiscal Q4 net loss of $1.36 per diluted share, compared with $1.33 loss a year earlier.
Analysts surveyed by FactSet expected a loss of $1.16.
Revenue for the quarter ended Sept. 30 declined to $14.6 million from $18.9 million a year earlier. Analysts polled by FactSet expected $18 million.
The company said its funds will be sufficient to meet the anticipated cash requirements of its existing business and development programs into fiscal 2027.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。